1. Albin N, Massade L, Gouyette A (1997) Value and applications of pharmacogenetics in oncology and hematology. Bull Cancer 84:643
2. Allerheiligen S, Johnson R, Hatcher B, Freeman K, Tarassoff P, Voi M, Dorr A (1994) Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc Am Soc Clin Oncol 12:136
3. Anderson LW, Ludeman SM, Colvin OM, Grochow LB, Strong JM (1995) Quantitation of 4-hydroxycyclophosphamide/aldophos-phamide, an activated metabolite of cyclophosphamide. J Chromatogr B Biomed Appl 667:247
4. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM (1996) Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2:1481
5. Arneson D, Evans E, Kovatch R, Moore R, Morton T, Tomaszewski J, Smith AC (1995) Preclinical toxicology and pharmacology of flavopiridol (NSC-649890) in rats and dogs. Proc Am Assoc Cancer Res 36:366